AEZS : Analysis & Opinions

  1. SPA for Aeterna Zentaris Candidate - Analyst Blog

    January 2, 2013
    Aeterna Zentaris Inc. (AEZS) recently announced that its oncology candidate, AEZS-108 (doxorubicin peptide conjugate) will ...
  2. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  3. Biotechs Ready To Roll

    February 16, 2011
    Biotechs Ready To Roll
Trading Center